Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.

Antiviral therapy - 1 Jan 2009

Boivin Guy, Goyette Nathalie, Rollag Halvor, Jardine Alan G, Pescovitz Mark D, Asberg Anders, Ives Jane, Hartmann Anders, Humar Atul

Abstract excerpt

BACKGROUND: The rate of cytomegalovirus (CMV) mutations conferring ganciclovir resistance was assessed in a trial comparing intravenous ganciclovir and oral valganciclovir for treatment of CMV disease in solid organ transplant (SOT) recipients. METHODS: Viral genes (UL97 and UL54) conferring ganciclovir resistance were amplified and sequenced from blood samples collected at days 0 (before therapy), 21 (end of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Cytomegalovirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytomegalovirus Infections

Share to DNA-Directed DNA Polymerase

Share to Ganciclovir

Share to Injections, Intravenous

Share to Organ Transplantation

Share to Phosphotransferases (Alcohol Group Acceptor)

Source

Identifiers

PMID: 19704173

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.PMID 19704173Read ↗

Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.Semantic proximity Read ↗

Detection of cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance.Semantic proximity Read ↗

Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.Semantic proximity Read ↗

The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection.Semantic proximity Read ↗

Improvement in detecting cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance using next generation sequencingSemantic proximity Read ↗

Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.Semantic proximity Read ↗

Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis.Semantic proximity Read ↗

Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis.Semantic proximity Read ↗

Molecular Analysis of Ganciclovir-Resistant Cytomegalovirus in Renal Transplant Recipients with High Viral Load.Semantic proximity Read ↗

Study of cytomegalovirus resistance in allogeneic hematopoietic cell transplant recipients.Semantic proximity Read ↗

Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.Semantic proximity Read ↗

Kinetics of host immune responses and cytomegalovirus resistance in a liver transplant patient.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.